Aimmune Therapeutics announces AR101 for peanut allergy demonstrates consistent efficacy and safety in new analysis of PALISADE and ARTEMIS phase III clinical data -

Aimmune Therapeutics announces AR101 for peanut allergy demonstrates consistent efficacy and safety in new analysis of PALISADE and ARTEMIS phase III clinical data
Information type: Media and commentaries
Source: DiabetesTeam
Specialities: Allergy and immunology
Summary
Across both studies, which met primary efficacy endpoints, median tolerated dose of peanut protein increased from 10 to 1000mg between entry and exit food challenges. Approximately two-thirds of patients tolerated 600mg and over half tolerated 1,000 mg in exit food challenge.
UKMi comment

AR101 is an investigational biologic drug being developed for use during oral immunotherapy to reduce the incidence and severity of allergic reactions following exposure to peanuts. Its Biologics License Application is under review by the FDA, which granted it Breakthrough Therapy Designation in 2015 for the desensitisation of peanut-allergic patients 4 to 17 years of age. The European Medicines Agency is reviewing the Marketing Authorization Application for AR101 which was submitted in June 2019.
Related links: